m6A-modification weakens MDA5 mRNA stability and antiviral ability.
(A) Silence efficiency of si-METTL3 and si-METTL14 measured. Three siRNAs of METTL3 and METTL14 were transfected into MPC cells for 48 h respectively. (B) METTL3 immunoprecipitates with METTL14. EPC cells (1×107) were co-transfected with METTL3-Myc and METTL14-Flag expression plasmids for 24 h, followed by immunoprecipitation (IP) with anti-Myc. (C) METTL3 and METTL14 significantly increased the m6A content. MPCs were transfected with si-Ctrl or si-METTL3 or si-METTL14 and MKCs were transfected with vector or METTL3 or METTL14 plasmids for 48 h, then the m6A level was measured by colorimetry. (D) METTL3 and METTL14 overexpressed MKC cells seeded in 48-well plates overnight were treated with SCRV at the dose indicated for 48 h. Then, cell monolayers were fixed with 4% paraformaldehyde and stained with 1% crystal violet. (E) MKC cells were transfected with pcDNA3.1 vector and METTL3 or METTL14 expression plasmid for 24 h, then infected with SCRV (MOI = 5) for 24 h. The qPCR analysis was conducted for SCRV-M and SCRV-G RNA levels. (F) The m6A level alteration of MDA5 upon METTL3 or METTL14 knockdown or overexpression was examined by MeRIP-qPCR. MPC cells were transfected with si-Ctrl or si-METT3 and MKC cells were transfected with vector or METTL3 or METTL14 plasmids for 48 h. (G and H) MPC cells were transfected with si-Ctrl, si-METTL3 or METTL14 and MKC cells were transfected with vector, METTL3, or METTL14 plasmids for 48 h, the expression of MDA5 was detected by qRT-PCR and Western blotting. (I) MPC cells were transfected with si-Ctrl, si-METTL3, or si-METTL14, and MKC cells were transfected with vector, METTL3, or METTL14 plasmids, then 5 µg/ml actinomycin D was added to the cells for 0 h, 2 h, and 4 h. The half-life of MDA5 was analyzed by qRT-PCR. (J) MKC cells were transfected with vector or METTL3&14 plasmids for 24 h and then treated with Cycloleucine (CL) for 24 h in a final concentration of 20 mM. The expression of MDA5 was detected by qRT-PCR and Western blotting. (K) MKC cells were transfected with vector or METTL3&14 plasmids for 24 h and then treated with CL for 24 h at 20 mM, then 5 µg/ml actinomycin D was added to the cells for 0 h, 2 h, and 4 h. The half-life of MDA5 was analyzed by qRT-PCR. (L) MKC cells were transfected with vector or METTL3&14 plasmids for 24 h and stimulated with SCRV (MOI = 5) for 24 h, then the expression of MDA5 was detected by qRT-PCR and Western blotting. (M) MKC cells seeded in 48-well plates overnight were transfected with MDA5 or MDA5+METTL3&14 plasmids for 48 h, then the expression of MDA5 was detected by qRT-PCR. (N) MKC cells seeded in 48-well plates overnight were transfected with MDA5 or MDA5+METTL3&14 plasmids were treated with SCRV at the dose indicated for 48 h. Then, cell monolayers were fixed with 4% paraformaldehyde and stained with 1% crystal violet. (O) MKC cells were transfected with MDA5 or MDA5 + METTL3&14 plasmids for 24 h, then infected with SCRV (MOI = 5) for 24 h. The qPCR analysis was conducted for SCRV-M and SCRV-G RNA levels. All data presented as the means ± SE from at least three independent triplicated experiments. **, p < 0.01; *, p < 0.05 versus the controls.